Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. by Michael J Thomenius, Jennifer Totman, Darren Harvey, Lorna H Mitchell, Thomas V Riera, Kat Cosmopoulos, Alexandra R Grassian, Christine Klaus, Megan Foley, Elizabeth A Admirand, Haris Jahic, Christina Majer, Tim Wigle, Suzanne L Jacques, Jodi Gureasko, Dorothy Brach, Trupti Lingaraj, Kip West, Sherri Smith, Nathalie Rioux, Nigel J Waters, Cuyue Tang, Alejandra Raimondi, Michael Munchhof, James E Mills, Scott Ribich, Margaret Porter Scott, Kevin W Kuntz, William P Janzen, Mikel Moyer, Jesse J Smith, Richard Chesworth, Robert A Copeland, P Ann Boriack-Sjodin

Get full text